Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global influenza vaccines vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m in 2018. The moderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza vaccines, and the approval of new influenza vaccines vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza vaccines. The upcoming influenza vaccines vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccines vaccine and Vepacel, and universal influenza vaccines vaccines such as BVX-M001, MVA-NP+M1, Flu-v and others. The influenza vaccines vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVRS-100 with Fluzone and IC31 Seasonal influenza vaccines Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian influenza vaccines (H5N1) Oral Vaccine), nasal vaccine (influenza vaccines Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic influenza vaccines Vaccine Patch).

Scope

The report provides information on the key drivers and challenges of the influenza vaccines market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) influenza vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as conjugate vaccine, combinational vaccine, polysachharide vaccines and others.
- Analysis of the current and future competition in the seven key countries influenza vaccines market. Key market players covered are Novartis AG, GlaxoSmithKline, Sanofi, Pfizer Inc, LG Life Sciences, Sinovac Biotech and Eurocrine Vaccines.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the influenza vaccines therapeutics market.
- Analysis of key recent licensing and partnership agreements in influenza vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global influenza vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global influenza vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What is the next big thing in the global influenza vaccines market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Influenza Vaccines - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 8
2.3.1 Types of Influenza Virus 8
2.3.2 Source of Influenza Virus 9
2.3.3 Drifting and Shifting of Influenza Virus 9
2.4 Signs and Symptoms 11
2.5 Diagnosis 11
2.6 Treatment and Management Options 13
2.7 GlobalData Pipeline Report Guidance 14
3 Influenza Vaccines: Market Characterization 15
3.1 Influenza Vaccines Market Size (2005-2010) - Global 15
3.2 Influenza Vaccines Market Forecast (2011-2018) - Global 16
3.3 Influenza Vaccines Market Size (2005-2010) - The US 17
3.4 Influenza Vaccines Market Forecast (2011-2018) - The US 18
3.5 Influenza Vaccines Market Size (2005-2010) - France 19
3.6 Influenza Vaccines Market Forecast (2011-2018) - France 20
3.7 Influenza Vaccines Market Size (2005-2010) - Germany 21
3.8 Influenza Vaccines Market Forecast (2011-2018) - Germany 22
3.9 Influenza Vaccines Market Size (2005-2010) - Italy 23
3.10 Influenza Vaccines Market Forecast (2011-2018) - Italy 24
3.11 Influenza Vaccines Market Size (2005-2010) - Spain 25
3.12 Influenza Vaccines Market Forecast (2011-2018) - Spain 26
3.13 Influenza Vaccines Market Size (2005-2010) - The UK 27
3.14 Influenza Vaccines Market Forecast (2011-2018) - The UK 28
3.15 Influenza Vaccines Market Size (2005-2010) - Japan 29
3.16 Influenza Vaccines Market Forecast (2011-2018) - Japan 30
3.17 Drivers and Barriers for the Influenza Vaccines Market 31
3.17.1 Drivers for the Influenza Vaccines Market 31
3.17.2 Barriers for the Influenza Vaccines Market 32
3.18 Opportunity and Unmet Need Analysis 33
3.19 Key Takeaway 34
4 Influenza Vaccines: Competitive Assessment 35
4.1 Overview 35
4.2 5.1.1 Strategic Competitor Assessment 35
4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market 36
4.3.1 Fluarix 36
4.3.2 FluLaval 37
4.3.3 Flumist 38
4.3.4 Fluvirin 39
4.3.5 Fluzone 39
4.4 Key Takeaway 40
5 Influenza Vaccines - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Influenza Vaccines Pipeline - Pipeline by Phases of Development 42
5.2.2 Influenza Vaccines - Regulatory Filed Products 42
5.2.3 Influenza Vaccines - Phase III Pipeline 43
5.2.4 Influenza Vaccines - Phase II Pipeline 43
5.2.5 Influenza Vaccines - Phase I Pipeline 44
5.2.6 Influenza Vaccines - Pre-Clinical Pipeline 45
5.2.7 Influenza Vaccines - Discovery Pipeline 46
5.2.8 Technology Trends Analytical Framework 47
5.3 Influenza Vaccines - Clinical Pipeline by Types of Vaccine 49
5.4 Influenza Vaccines - Promising Drugs Under Clinical Development 49
5.5 Molecule Profile for Promising Drugs Under Clinical Development 50
5.5.1 FluBlok 50
5.5.2 Flu Vaccine 51
5.5.3 MEDI 3250 51
5.5.4 A-04-01D Vaccine 52
5.5.5 H5N1 Pandemic Influenza Vaccine 52
5.5.6 Vepacel 52
5.6 Key Takeaway 52
6 Influenza Vaccines: Clinical Trials Mapping 53
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Prominent Sponsors 56
6.5 Top Companies Participating in Influenza Vaccines Clinical Trials 58
7 Influenza Vaccines: Strategic Assessment 59
7.1 Key Events Impacting the Future Market 59
7.2 Influenza Vaccines: Implications for Future Market Competition 60
8 Influenza Vaccines: Future Players 61
8.1 Introduction 61
8.2 Company Profiles 62
8.2.1 AstraZeneca PLC 62
8.2.2 GlaxoSmithKline plc 63
8.2.3 Novartis AG 65
8.2.4 Baxter International Inc. 66
9 Influenza Vaccines: Licensing and Partnership Deals 68
10 Influenza Vaccines: Appendix 83
10.1 Market Definitions 83
10.2 Abbreviations 83
10.3 Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 86
10.3.3 Forecasting 86
10.3.4 Primary Research 88
10.3.5 Expert Panel Validation 89
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Bibliography 89

List of Tables

Table 1: Influenza Vaccines Market, Global, Revenue ($m), 2005-2010 15
Table 2: Influenza Vaccines Market, Global, Forecast ($m), 2011-2018 16
Table 3: Influenza Vaccines Market, The US, Revenue ($m), 2005-2010 17
Table 4: Influenza Vaccines Market, The US, Forecasts ($m), 2011-2018 18
Table 5: Influenza Vaccines Market, France, Revenue ($m), 2005-2010 19
Table 6: Influenza Vaccines Market, France, Forecasts ($m), 2011-2018 20
Table 7: Influenza Vaccines Market, Germany, Revenue ($m), 2005-2010 21
Table 8: Influenza Vaccines Market, Germany, Forecasts ($m), 2011-2018 22
Table 9: Influenza Vaccines Market, Italy, Revenue ($m), 2005-2010 23
Table 10: Influenza Vaccines Market, Italy, Forecasts ($m), 2011-2018 24
Table 11: Influenza Vaccines Market, Spain, Revenue ($m), 2005-2010 25
Table 12: Influenza Vaccines Market, Spain, Forecasts ($m), 2011-2018 26
Table 13: Influenza Vaccines Market, The UK, Revenue ($m), 2005-2010 27
Table 14: Influenza Vaccines Market, The UK, Forecasts ($m), 2011-2018 28
Table 15: Influenza Vaccines Market, Japan, Revenue ($m), 2005-2010 29
Table 16: Influenza Vaccines Market, Japan, Forecasts ($m), 2011-2018 30
Table 17: Influenza Vaccines - Regulatory Filed Products, 2011 42
Table 18: Influenza Vaccines - Phase III Pipeline, 2011 43
Table 19: Influenza Vaccines - Phase II Pipeline, 2011 43
Table 20: Influenza Vaccines - Phase I Pipeline, 2011 44
Table 21: Influenza Vaccines - Pre-Clinical Pipeline, 2011 45
Table 22: Influenza Vaccines - Discovery Pipeline, 2011 46
Table 23: Influenza Vaccines - Most Promising Drugs Under Clinical Development, 2011 49
Table 24: Influenza Vaccines - Clinical Trials by Country, 2011 53
Table 25: Influenza Vaccines - Clinical Trials by Phase, 2011 54
Table 26: Influenza Vaccines - Clinical Trials by Status, 2011 55
Table 27: Influenza Vaccines - Overall Sponsors, 2011 56
Table 28: Influenza Vaccines - Prominent Sponsors, 2011 57
Table 29: Influenza Vaccines - Top Companies Participating in Clinical Trials, 2011 58
Table 30: Astrazeneca - Influenza Pipeline Products, 2011 63
Table 31: GlaxoSmithKline - Influenza Pipeline Products, 2011 65
Table 32: Novartis AG - Influenza Pipeline Products, 2011 66
Table 33: Baxter International - Influenza Pipeline Products, 2011 67
Table 34: Influenza Vaccines: Licensing and Partnership Deals, 2011 68

List of Figures

Figure 1: Comparison of Seasonal and Pandemic Influenza 7
Figure 2: Comparison of Influenza A, B and C 9
Figure 3: Comparison of Influenza and the Common Cold 11
Figure 4: Influenza Virus Testing Methods 12
Figure 5: Clinical Algorithm for Consideration in the Assessment of Persons with Mild or Uncomplicated Influenza Illness 13
Figure 6: Influenza Vaccines Market, Global, Revenue ($m), 2005-2010 15
Figure 7: Influenza Vaccines Market, Global, Forecast ($m), 2011-2018 16
Figure 8: Influenza Vaccines Market, The US, Revenue ($m), 2005-2010 17
Figure 9: Influenza Vaccines Market, The US, Forecast ($m), 2011-2018 18
Figure 10: Influenza Vaccines Market, France, Revenue ($m), 2005-2010 19
Figure 11: Influenza Vaccines Market, France, Forecast ($m), 2011-2018 20
Figure 12: Influenza Vaccines Market, Germany, Revenue ($m), 2005-2010 21
Figure 13: Influenza Vaccines Market, Germany, Forecast ($m), 2011-2018 22
Figure 14: Influenza Vaccines Market, Italy, Revenue ($m), 2005-2010 23
Figure 15: Influenza Vaccines Market, Italy, Forecast ($m), 2011-2018 24
Figure 16: Influenza Vaccines Market, Spain, Revenue ($m), 2005-2010 25
Figure 17: Influenza Vaccines Market, Spain, Forecast ($m), 2011-2018 26
Figure 18: Influenza Vaccines Market, The UK, Revenue ($m), 2005-2010 27
Figure 19: Influenza Vaccines Market, The UK, Forecast ($m), 2011-2018 28
Figure 20: Influenza Vaccines Market, Japan, Revenue ($m), 2005-2010 29
Figure 21: Influenza Vaccines Market, Japan, Forecast ($m), 2011-2018 30
Figure 22: Opportunity and Unmet Need in the Influenza Vaccines Market 33
Figure 23: Influenza Vaccines - Strategic Competitor Assessment, 2010 36
Figure 24: Influenza Vaccines - Pipeline by Phase of Development, 2011 42
Figure 25: Influenza Vaccines - Technology Trends Analytics Framework, 2011 47
Figure 26: Influenza Vaccines - Technology Trends Analytics Framework - Description, 2011 48
Figure 27: Influenza Vaccines - Pipeline by Types of Vaccines, 2011 49
Figure 28: Influenza Vaccines - Clinical Trials by Country, 2011 53
Figure 29: Influenza Vaccines - Clinical Trials by Phase, 2011 54
Figure 30: Influenza Vaccines - Clinical Trials by Status, 2011 55
Figure 31: Influenza Vaccines - Overall Sponsors, 2011 56
Figure 32: Influenza Vaccines - Prominent Sponsors, 2011 57
Figure 33: Influenza Vaccines - Top Companies Participating in Clinical Trials, 2011 58
Figure 34: Influenza Vaccines Market, Drivers and Barriers, 2011 59
Figure 35: Implications for Future Market Competition in the Influenza Vaccines Market, 2011 60
Figure 36: Influenza Vaccines Market - Pipeline by Company, 2011 61
Figure 37: GlobalData Market Forecasting Model 88

Companies Mentioned
AstraZeneca PLC
GlaxoSmithKline plc
Novartis AG
Baxter International Inc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.